NeoBOMB1

Drug Profile

NeoBOMB1

Alternative Names: 177Lu-NeoBOMB1; 68Ga-NeoBOMB1

Latest Information Update: 18 Oct 2016

Price : $50

At a glance

  • Originator Erasmus University Rotterdam; National Center for Scientific Research Demokritos
  • Class Imaging agents; Neuropeptides; Organometallic compounds; Peptides; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Bombesin receptor antagonists; Ionising radiation emitters; Neuropeptide receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Prostate cancer

Most Recent Events

  • 07 Jun 2016 Medical University Innsbruck and European Union plan the phase I/IIa MITIGATE-NeoBOMB1 trial for Gastrointestinal stromal tumours (Diagnosis) in Austria (IV) (9197364; NCT02931929)
  • 07 Jun 2016 Advanced Accelerator Application plans clinical trials in Prostate cancer and Breast cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top